Abstract
In late 2007 and early 2008, a cluster of adverse events in patients receiving Heparin Sodium Injection occurred in the United States and in some countries in Europe. The adverse events were reported as being “allergic type” reactions, chiefly characterized by acute hypotension, nausea, and shortness of breath. The root cause of the cluster of adverse events was determined to be a contamination of the heparin by oversulfated chondroitin sulfate. The isolation and structure determination of this contaminant was accomplished by an FDA-led consortium of academic and government laboratories and independently by Baxter Healthcare, whose vial products were first identified in the USA as being associated with the adverse events. Oversulfated chondroitin sulfate was shown to produce acute hypotension in animal models, demonstrating that it was most likely the causative agent responsible for certain of the reported adverse events in patients receiving the contaminated heparin products.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Barzu T, Level M, Petitou M et al (1993) Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect. J Med Chem 36:3546–3555
Blossom DB, Kallen AJ, Patel PR et al (2008) Outbreak of adverse reactions associated with contaminated heparin . N Engl J Med 359:2674–2684
Food and Drug Administration (2008) Information on heparin sodium injection. http://www.fda.gov/cder/drug/infopage/heparin/default.htm#screening
Guerrini M, Besccati D, Schriver Z et al (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669–675
Guerrini M, Zhang Z, Shriver Z et al (2009) Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci USA 106:16956–16961
Hu P, Fang L, Chess EK (2009) Source-induced fragmentation of heparin, heparin, and galactosaminoglycans and application. Anal Chem 81:2332–2343
Kishimoto TK, Viswanathan K, Ganguly T et al (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358:2457–2467
Korir AK, Limtiaco JFK, Gutierrez SM et al (2008) Ultraperformance ion-pair liquid chromatography coupled to electrospray time-of-flight mass spectrometry for compositional profiling and quantification of heparin and heparan sulfate. Anal Chem 80:1297–1306
Maruyama T, Toida T, Imanari T et al (1998) Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 306:35–43
McKee J, Bairstow S, Szabo C et al (2010) Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin. J Clin Pharmacol [Epub ahead of print, 10 February 2010], doi:10.1177/0091270009355158
Patel RP, Narkowic C, Hutchinson JP et al (2008) A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins. J Pharm Biomed Anal 46:30–35
Pavão MSG, Mourão PAS, Mulloy B et al (1995) A unique dermatan sulfate-like glycosaminoglycan from ascidian. J Biol Chem 270:31027–31036
Petitou M, Coudert C, Level M et al (1992) Selectively O-acylated glycosaminoglycan derivatives. Carbohydr Res 236:107–119
Trehy ML, Reepmeyer JC, Kolinski RE et al (2009) Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal 49:670–673
Viskov C, Boulet E, Hubert P et al (2009) Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Clin Appl Thromb Hemost 15:395–401
Waeber G, Schapira M, Waeber B et al (1988) Hypotensive effect of the active fragment derived from factor XII is mediated by an activation of the plasma kallikrein-kinin system. Circ Shock 26:75–382
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Chess, E.K. et al. (2012). Case Study: Contamination of Heparin with Oversulfated Chondroitin Sulfate. In: Lever, R., Mulloy, B., Page, C. (eds) Heparin - A Century of Progress. Handbook of Experimental Pharmacology, vol 207. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-23056-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-23056-1_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-23055-4
Online ISBN: 978-3-642-23056-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)